Wearable psychedelics could be coming soon, giving users the ultimate level of control over their experience. The adjustable subcutaneous device from Bexson gives users the ability to tailor their trip, setting the intensity, depth, and duration of the experience. The device also allows users to change the settings and dosage on the device during a trip. The wearable psychedelics would be monitored by a healthcare provider and regulated by a medically-approved dosage.
There are a variety of companies developing wearable psychedelics. The company’s products will allow users to use psychedelics without a doctor. The company also expects to launch a clinical trial for its psychedelic-assisted therapy. The pharmaceutics isn’t available yet, but the team plans to continue working on the products and developing a pharmaceutical.
Bexson Biomedical Develops a Wearable Ketamine Pump
Bexson is working with medical packaging manufacturer Stevanato Group to manufacture its wearable ketamine pump. Its founders, Gregg Peterson and Jeffrey Becker believe that ketamine can offer an alternative to opioids and have partnered with a psychiatrist.
Bexson Biomedical is developing a wearable ketamine pump that works on the principles of an insulin pump. It is designed to be implanted into the body, delivering a dose of ketamine to the brain in the appropriate amounts to create the desired effect. The company claims that the wearable ketamine pump works by releasing 20 to 70 milligrams of ketamine in a slow drip. The dose is low enough to cause no hallucinations but high enough to create a psychoactive effect. The dosage of psychedelics is not standardized, so the ideal dosage varies from person to person. In addition, the length of the trip varies with the user’s metabolism and liver enzymes.
The device could be in human trials as early as 2022. The perfect psychedelic dose differs from person to person and lies somewhere between the “is it working?” And the “run! The moon is chasing us!” Stage. However, scientists are trying to develop better delivery systems.
Wearable Psychedelics Could Give Users The Maximum Control Over Their Trip
The new technology can revolutionize the way that psychedelics are administered. The subcutaneous Bexson pump allows users to fine-tune their psychedelic experience. They can pre-program how deep they want to go, how long they want to stay in the trance state, and how much to take. Once the device is appropriately tuned, users can increase their infusion rate to reach the desired level of experience. However, this requires careful monitoring by healthcare professionals to avoid overdose.
Wearable psychedelics could give users greater control over their trips. Researchers are working to develop a device that can deliver precise doses of psychedelics through the skin. This new technology could allow people to fine-tune the length and intensity of their psychedelic experience, and it might even allow them to pre-program their psychedelics. The adjustable subcutaneous device would be similar to an insulin pump and allow patients to program the duration and depth of their psy-trips themselves.
Wearable psychedelics could soon give users maximum control over their trip. The device works by allowing users to take the drug without leaving their homes. The pump is compatible with most electronic devices and is designed to deliver the drug to the body subcutaneously.
Bexson Biomedical Plans to Conduct Human Trials in 2020
Bexson Biomedical has partnered with medical device maker Stevanato Group to develop a wearable ketamine device. The company has already produced a ketamine microdosing device for clinical trials. It is only available in the Netherlands, but the company hopes to introduce it to the general public by 2022. The company has stated that it plans to conduct human trials in 2020 and aims for FDA approval in 2025 or 2026.
The company has partnered with the Lieber Institute for Brain Development and is advancing multiple unnamed drug candidates through the discovery stage. As long as these trials go well, the product could be available in the market as early as 2022. These companies have a long track record in developing psychedelic products and are now announcing a successful launch.
MINDCURE Working on Developing Ketamine-assisted Psychotherapy
In the meantime, several other companies are aiming to develop wearable devices. MINDCURE is a biotechnology company that is working on developing ketamine-assisted psychotherapy. It plans to develop these products in the future and expand its offerings into other psychedelic substances. The first product is a prototype that allows users to experience ketamine.
Improve The Way Ketamine is Administered to Provide Psychedelic-assisted Psychotherapy
One private company has launched a project that is working to provide psychedelics-assisted psychotherapy. The company aims to leverage genomic and biological information to improve the way ketamine is administered. It also plans to open its clinic in Jamaica, focusing on psilocybin-assisted therapy for eating disorders.
There is a Growing Psychedelic Industry
While these technologies are still in the early stages, there is a growing psychedelic industry. This sector is growing fast, and some companies are already making psychedelic products that are more accessible and affordable than current methods. Bexson Biomedical, for example, is working with three DEA-approved laboratories to develop a psilocybin-based drug.
The technology is mainly for medical use and should be safe for recreational use. It is not yet commercially available. Its use in the medical community is not limited to recreational purposes. It could even be used for therapeutic purposes in the future. It is also used to treat substance-related disorders, such as addiction. It will also be available in a wearable form for the general public.